External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews
- PMID: 16434911
- PMCID: PMC2567101
- DOI: 10.1097/01.mlr.0000196978.34283.a6
External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews
Abstract
Background: Although Medicare claims data have been increasingly used to examine the patterns and outcomes of cancer chemotherapy, their external validity has not been well studied.
Objectives: We sought to validate Medicare claims for chemotherapy compared with medical chart reviews.
Patients and methods: We completed medical chart reviews for 1228 women who were diagnosed with breast cancer at age 65 and older between 1993 and 1999 in New Mexico that were linked with Medicare claims data, achieving an estimated sensitivity of more than 90% and a 0.05 level of precision.
Results: Of the 150 subjects identified by Medicare claims as receiving chemotherapy within 6 months of diagnosis, 75% were confirmed by medical records as having received chemotherapy. Of the remaining 25% of cases without chart verification, (1) 33 cases had 7 or more claims for chemotherapy and also had specific chemotherapy drugs indicated in Medicare data, representing 22% (33/150) of all cases that received chemotherapy according to Medicare claims and (2) 4 cases had 1 to 6 claims for chemotherapy, representing 3% (4/150) of all cases with claims for chemotherapy. Of those 1078 subjects who did not receive chemotherapy according to Medicare claims, more than 99% were confirmed by chart reviews. Observed agreement on chemotherapy between Medicare claims and chart reviews was 94% and overall reliability (kappa) was 0.69 (95% confidence interval = 0.63-0.76).
Conclusions: Of cases identified as receiving chemotherapy by Medicare claims, 97% had strong evidence and only 3% had weak evidence for receiving this therapy.
Similar articles
-
Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.Ann Epidemiol. 2012 Nov;22(11):807-13. doi: 10.1016/j.annepidem.2012.08.001. Epub 2012 Sep 1. Ann Epidemiol. 2012. PMID: 22948184
-
Utility of the SEER-Medicare data to identify chemotherapy use.Med Care. 2002 Aug;40(8 Suppl):IV-55-61. doi: 10.1097/01.MLR.0000020944.17670.D7. Med Care. 2002. PMID: 12187169
-
Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.J Clin Epidemiol. 2006 Jan;59(1):53-60. doi: 10.1016/j.jclinepi.2005.06.002. Epub 2005 Sep 30. J Clin Epidemiol. 2006. PMID: 16360561 Free PMC article.
-
Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.Med Care. 2014 Sep;52(9):e58-64. doi: 10.1097/MLR.0b013e318277eba5. Med Care. 2014. PMID: 23222532 Free PMC article.
-
Medicare Advantage Chart Reviews Are Associated With Billions in Additional Payments for Some Plans.Med Care. 2021 Feb 1;59(2):96-100. doi: 10.1097/MLR.0000000000001412. Med Care. 2021. PMID: 32925467 Free PMC article. Review.
Cited by
-
Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer.Med Oncol. 2013 Mar;30(1):419. doi: 10.1007/s12032-012-0419-1. Epub 2013 Jan 6. Med Oncol. 2013. PMID: 23292872
-
Concordance Between Electronic Health Record Data and Medicare Part D Claims Data for Oral Anticancer Drug Use.JAMA Netw Open. 2020 Apr 1;3(4):e203821. doi: 10.1001/jamanetworkopen.2020.3821. JAMA Netw Open. 2020. PMID: 32352527 Free PMC article.
-
Racial variation in breast cancer treatment among Department of Defense beneficiaries.Cancer. 2012 Feb 1;118(3):812-20. doi: 10.1002/cncr.26346. Epub 2011 Jul 15. Cancer. 2012. PMID: 21766298 Free PMC article.
-
Comparison of SEER Treatment Data With Medicare Claims.Med Care. 2016 Sep;54(9):e55-64. doi: 10.1097/MLR.0000000000000073. Med Care. 2016. PMID: 24638121 Free PMC article.
-
Validation of electronic data on chemotherapy and hormone therapy use in HMOs.Med Care. 2013 Oct;51(10):e67-73. doi: 10.1097/MLR.0b013e31824def85. Med Care. 2013. PMID: 22531648 Free PMC article.
References
-
- Whittle J, Steinberg EP, Anderson GF, et al. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Med Care. 1991;29:1226–1236. - PubMed
-
- Fleming C, Fisher ES, Chang CH, et al. Studying outcomes and hospital utilization in the elderly. The advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care. 1992;30:377–391. - PubMed
-
- Nattinger AB, Gottlieb MS, Veum J, et al. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992;326:1102–1107. - PubMed
-
- Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732–748. - PubMed
-
- Lauderdale DS, Furner SE, Miles TP, et al. Epidemiologic uses of Medicare data. Epidemiol Rev. 1993;15:319–327. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical